Neurotech International Ltd
ASX:NTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neurotech International Ltd
Research & Development
Neurotech International Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neurotech International Ltd
ASX:NTI
|
Research & Development
-AU$8.5m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Research & Development
-AU$299.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Research & Development
-AU$5.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-15%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Research & Development
-AU$3.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Neurotech International Ltd
Glance View
Neurotech International Ltd. engages in the research, designing, marketing, and through third party manufacturers, production of wearable neurotechnology devices to assist with neurological conditions such as autism. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm operates through its wholly owned, Malta-based subsidiary AAT Research Limited. The firm is focusing on neuro-protective, anti-inflammatory and neuro-modulatory activities of NTI/Dolce cannabis strains. The firm through its class II device Mente is focused on development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is, a home therapy that is clinically proven to increase engagement and relaxation in autistic children with elevated Delta band brain activity.
See Also
What is Neurotech International Ltd's Research & Development?
Research & Development
-8.5m
AUD
Based on the financial report for Dec 31, 2025, Neurotech International Ltd's Research & Development amounts to -8.5m AUD.
What is Neurotech International Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-98%
Over the last year, the Research & Development growth was 3%. The average annual Research & Development growth rates for Neurotech International Ltd have been -33% over the past three years , -98% over the past five years .
